Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Weighted Average) (2021 - 2025)

Krystal Biotech's Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $28.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.23% year-over-year to $28.9 million; the TTM value through Dec 2025 reached $28.9 million, up 1.23%, while the annual FY2025 figure was $28.9 million, 1.23% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $28.9 million at Krystal Biotech, roughly flat from $29.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $29.0 million in Q3 2025 and bottomed at $21.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $26.7 million (2023), against an average of $26.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 18.17% in 2022 before it rose 0.83% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $22.2 million in 2021, then grew by 14.85% to $25.5 million in 2022, then grew by 6.52% to $27.2 million in 2023, then grew by 5.3% to $28.6 million in 2024, then rose by 1.23% to $28.9 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Shares Outstanding (Weighted Average) are $28.9 million (Q4 2025), $29.0 million (Q3 2025), and $28.9 million (Q2 2025).